Genentech Executive Jason Ehrlich Joins Kodiak Sciences C-Suite
Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients who have the “wet” form of age-related macular degeneration.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX
From Our Advertisers
